Answers are grounded in this paper and cite their sources.
Evaluating approaches to reduce treatment burden is a research priority among people with cystic fibrosis on highly effective modulators, including elexacaftor-tezacaftor-ivacaftor (ETI).
No takes yet. Share an insight, caveat, or question.
Mayer-Hamblett et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: